Who are Faslodex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natazia, Ortho Evra, Elocon, Gynorest, Progesterone, Aygestin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fulvestrant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Faslodex — Competitive Intelligence Brief

Faslodex (fulvestrant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen Receptor Antagonist [EPC]. Area: Oncology.

marketed Estrogen Receptor Antagonist [EPC] Progesterone receptor Oncology Live · refreshed every 30 min

Target snapshot

Faslodex (fulvestrant) — AstraZeneca. Faslodex works by binding to and degrading the estrogen receptor, preventing it from promoting the growth of cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Faslodex TARGET	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Ortho Evra	NORELGESTROMIN		marketed	Estrogen [EPC]	Progesterone receptor	2001-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	marketed	Corticosteroid	Progesterone receptor	1987-01-01
Gynorest	DYDROGESTERONE	Solvay	marketed	dydrogesterone	Progesterone receptor	1982-01-01
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01
Aygestin	NORETHINDRONE ACETATE	Duramed Res	marketed	Estrogen [EPC]	Progesterone receptor	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-29 — Elocon · 7544192 · Method of Use · US
2027-06-12 — Elocon · 8025635 · Formulation · US
2028-01-30 — Natazia · 8153616 · US
2031-10-03 — Elocon · 10357640 · Method of Use · US
2032-02-08 — Elocon · 8763222 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-03-13 — Elocon · 10406332 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US
2034-11-24 — Elocon · 10232152 · Formulation · US

Sponsor landscape (Estrogen Receptor Antagonist [EPC] class)

· 1 drug in this class
AstraZeneca · 1 drug in this class
Eli Lilly And Co · 1 drug in this class
Stemline Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Faslodex — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab